Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

TerminatedOBSERVATIONAL
Enrollment

391

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

May 31, 2018

Study Completion Date

August 31, 2018

Conditions
HIV
Interventions
DRUG

Tesamorelin for injection

Daily 2 mg subcutaneous injections of Tesamorelin

Trial Locations (31)

10011

Ricky K. Hsu, MD, PC, New York

14215

University at Buffalo, State University of NY, Erie County Medical Center, Buffalo

19611

Reading Hospital and Medical Center, West Reading

20009

Dupont Circle Physician's Group, Washington D.C.

20036

Capital Medical Associates, PC, Washington D.C.

30309

Absolute Care Medical Center, Atlanta

32805

Orange County Health Department, Orlando

32809

Orange County Health Department, Orlando

33133

The Kinder Medical Group-AHF, Miami

33305

Rowan Tree Medical, P.A., Wilton Manors

33316

Gary J. Richmond, M.D., PA, Fort Lauderdale

44304

Summa Health Care System, Akron

60657

Northstar Medical Center, Chicago

62702

Southern Illnois University School of Medicine, Springfield

63108

Southhampton Clinical Research, Inc. d.b.a. Central West Clinical Research, St Louis

63139

Southampton Healthcare, Inc., St Louis

74127

Virginia Mason Medical Center, Tulsa

75216

Dallas VA Medical Center, Dallas

75235

University of Texas Southwestern Medical Center at Dallas, Dallas

77401

St. Hope Foundation, Inc., Bellaire

90035

University of California CARE Clinic, Los Angeles, Los Angeles

90048

Tower Infectious Diseases Medical Associates, Los Angeles

90095

Oasis Clinic, Los Angeles

92708

Pacific Coast Medical Group, Fountain Valley

93301

Franco Felizarta, MD, Bakersfield

94121

VAMC, Infectious Disease Section 111W, San Francisco

98112

Virginia Mason Medical Center, Seattle

02114

Massachusetts General Hospital, Boston

01105

The Researth Institute, Springfield

48072-3436

Be Well Medical Center, P.C, Berkley

08244

South Jersey Unfectious Disease, Somers Point

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theratechnologies

INDUSTRY

NCT01579695 - Long-term Observational Study in HIV Subjects Exposed to EGRIFTA® | Biotech Hunter | Biotech Hunter